Company Overview

Zentek Ltd. is a Canadian intellectual property development and commercialization company focused on advanced materials, nanotechnology, and healthcare-related technologies. The company operates primarily in the graphene and nanomaterials sector, with activities spanning materials science, industrial coatings, diagnostics, and biotechnology applications. Zentek is listed on the TSX Venture Exchange under the ticker ZEN.V and evolved from a resource-focused company into a technology commercialization business centered on graphene-based innovation and proprietary platform technologies.

The company’s primary revenue and development focus has been tied to graphene-enhanced products, antimicrobial technologies, and aptamer-based diagnostic and therapeutic platforms. Zentek has pursued applications in healthcare, air filtration, corrosion protection, and industrial materials through internally developed intellectual property and strategic collaborations. A key element of its positioning is access to graphene-related expertise and proprietary formulations intended for commercial applications requiring antimicrobial performance, material durability, or advanced sensing capabilities. The company’s transition from mining exploration toward technology development was formalized through rebranding and strategic restructuring during the early 2020s.

Business Operations

Zentek’s operations are organized around technology development, intellectual property creation, and commercialization partnerships. Its principal business activities include graphene-based coatings and materials, healthcare technologies, and biotechnology initiatives. The company has developed and promoted products associated with antimicrobial coatings, HVAC filtration enhancements, and graphene-enabled industrial applications. Through Triera Biosciences, Zentek has also expanded into aptamer-based technologies targeting diagnostics and therapeutics research. Revenue generation has historically been limited relative to larger industrial peers and has been tied primarily to technology licensing, development agreements, product commercialization efforts, and related partnerships.

The company’s operations are primarily based in Canada, though its technology initiatives target broader international markets. Zentek controls proprietary intellectual property associated with graphene formulations, coating technologies, and aptamer development platforms. The company has collaborated with academic institutions, research organizations, and commercial partners to validate and scale applications for healthcare and industrial use. Public disclosures indicate ongoing efforts to secure regulatory approvals, commercialization agreements, and manufacturing relationships necessary for broader market adoption.

Strategic Position & Investments

Zentek’s strategic direction has focused on transitioning from research and development into commercial deployment of proprietary technologies. Growth initiatives have centered on scaling graphene-enhanced products for healthcare and industrial applications, including antimicrobial coatings and filtration technologies. The company has also emphasized biotechnology through investments in aptamer platforms designed for diagnostic and therapeutic applications. Public filings and investor materials indicate that Zentek views intellectual property ownership and application-specific innovation as core competitive advantages.

The acquisition and development of Triera Biosciences represented a significant expansion into biotechnology and life sciences. Zentek has also invested in product validation, regulatory pathways, and strategic collaborations intended to support commercialization. Emerging areas of focus include nanomaterials for infrastructure protection, environmental applications, and advanced healthcare technologies. While management has publicly discussed broader commercial potential across several sectors, the timing and scale of large-scale adoption remain dependent on market acceptance, regulatory developments, and commercialization execution. Certain future revenue expectations discussed publicly remain subject to uncertainty based on available public sources.

Geographic Footprint

Zentek is headquartered in Guelph, Ontario, Canada, and maintains its primary operational and corporate presence within Canada. The company’s research, development, and commercialization efforts have largely been centered in the Canadian market, including collaborations with Canadian research institutions and industry partners. Its historical resource-related interests were associated with northern Ontario graphite assets, though the company’s strategic emphasis has shifted toward technology development and commercialization.

Despite its Canadian base, Zentek has positioned several of its technologies for international application, particularly in healthcare, industrial coatings, and filtration markets. The company has referenced commercial opportunities in North America, and certain technologies may have relevance for broader international markets where antimicrobial standards, industrial protection, or advanced materials demand are growing. Data regarding extensive international operating infrastructure or large-scale foreign subsidiaries remains inconclusive based on available public sources.

Leadership & Governance

Zentek’s leadership has emphasized innovation-driven commercialization, intellectual property development, and strategic partnerships across advanced materials and biotechnology sectors. The company evolved from its earlier identity as Zen Graphene Solutions Ltd. under leadership focused on leveraging graphene-related technologies into commercially viable products. Management communications and public filings have consistently highlighted long-term value creation through proprietary technology platforms and cross-sector applications.

Key executives and leadership figures include:

• Greg Fenton – Chief Executive Officer
• Ryan Shacklock – Chief Financial Officer
• Francis Dubé – Vice President, Corporate Development
• Dr. Kenneth Reed – Director and scientific leadership contributor
• Vijay M. Vadlamudi – Leadership role associated with Triera Biosciences initiatives

The company’s governance structure includes a board of directors overseeing commercialization strategy, capital allocation, and technology development. Public disclosures through SEDAR+ filings, investor presentations, and corporate announcements indicate a leadership philosophy centered on research-driven innovation, strategic partnerships, and intellectual property monetization. Certain executive role changes and organizational responsibilities may vary over time based on company filings and public disclosures.